Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT07102043
Status
Recruiting
Apply to this trial

Conditions

  • Cystic Fibrosis Related Diabetes

Eligibility Criteria

Sex
ALL
Age
21 Years - 75 Years
Healthy Volunteers
Not accepted

Study Details

The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.

Key Dates

Start date
May 28, 2026
Status verified
May 2026
Primary completion
May 1, 2028
Completion
May 28, 2028

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: CFRD F508del +ETI
    CFRD with at least one copy of F508del currently on elexacaftor/tezacaftor/ivacaftor (CFRDF508del+ETI),
  • Arm: CFRD-ETI
    CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI).

Primary Outcome Measure

Disposition Index in CFRD [ Time Frame: Day 1 During the Mixed meal test ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama352294
Tavares R Donerlson, BA
[email protected]
2054848306
John M Mullin, BS
[email protected]
2672290194

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies